Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10371088" target="_blank" >RIV/00216208:11110/17:10371088 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/17:10371088

Result on the web

<a href="http://dx.doi.org/10.1038/bmt.2016.213" target="_blank" >http://dx.doi.org/10.1038/bmt.2016.213</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/bmt.2016.213" target="_blank" >10.1038/bmt.2016.213</a>

Result language

angličtina

Original language name

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

Original language description

In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The median time between ASCT and progression was 7.1 months. The median age was 56.1 years; tertiary International Prognosis Index (tIPI) observed at relapse was 0-2 in 71.6% of the patients and &gt;2 in 28.4%. The overall response rate to third-line chemotherapy was 44%. The median overall survival (OS) was 10.0 months (median follow-up: 32.8 months). Thirteen patients received an allogeneic SCT, and three a second ASCT. The median OS was shorter among patients who relapsed &lt;6 months (5.7 months) compared with those relapsing &gt;= 12 months after ASCT (12.6 months, P = 0.0221). The median OS in patients achieving CR, PR or no response after the third-line regimen was 37.7 (P&lt;0.0001), 10.0 (P = 0.03) and 6.3 months, respectively. The median OS varied according to tIPI: 0-2: 12.6 months and &gt;2: 5.3 months (P = 0.0007). In multivariate analysis, tIPI &gt;2, achievement of response and remission lasting &lt;6 months predicted the OS. This report identifies the prognostic factors for DLBCL relapsing after ASCT and thus helps to select patients for experimental therapy.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Bone Marrow Transplantation

ISSN

0268-3369

e-ISSN

—

Volume of the periodical

52

Issue of the periodical within the volume

2

Country of publishing house

GB - UNITED KINGDOM

Number of pages

6

Pages from-to

216-221

UT code for WoS article

000394134300009

EID of the result in the Scopus database

2-s2.0-84988369353